Clinical Trials Logo

Clinical Trial Summary

A single-center observational clinical trial will be performed for metastatic spinal tumors by stereotactic radiotherapy using TomoTherapy. In this study, we will explore the local control rate (LCR), disease-free progression time (PFS), overall survival time (OS), and pain relief in patients with spinal metastasis, so as to provide a basis for developing relevant guidelines or consensus.


Clinical Trial Description

In this observational single-arm study, a total of 45 patients with metastatic spinal tumors will be enrolled. The patients were aged between 18 and 75 years old. And all the subjects should meet the inclusion criteria and sign the informed consent. Meanwhile, the patients' medical history characteristics, including gender, age, imaging data (X-ray, CT, MRI, or PET-CT, etc.), primary tumor type, pathological type, previous treatment, previous disease history, tumor markers and bone metabolism indexes were collected and recorded on the CRF. The metastatic spinal tumors by stereotactic radiotherapy(SBRT) using TomoTherapy. The adiotherapy dose is 6Gy×5Fx, 5Gy×5Fx or 4Gy×5Fx according to the irradiation site. Treatment should be interrupted if there is severe bone marrow suppression, vertebral compression fracture, or radiation myelitis. The adjacentnormal tissue constrains refer to the UK SABR Consortium Guidelines (2022 version). Follow-up was performed 1 month after radiotherapy, thereafter every 3 months for 1-4 years. The parameters includ blood routine, liver and kidney function, bleeding and coagulation function, bone metabolism index, tumor markers, bone metastasis imaging examination. Tumor response will refer to the Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05808998
Study type Observational
Source Shanghai Zhongshan Hospital
Contact Li Zhang, MD
Phone 17821701209
Email zhang.li12@zs-hospital.sh.cn
Status Not yet recruiting
Phase
Start date April 1, 2023
Completion date April 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT04324645 - Active Symptom Monitoring in Patients Undergoing Radiation Therapy for Thoracic Malignancies
Completed NCT04776083 - Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients Phase 3
Completed NCT01635270 - Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma Phase 2
Terminated NCT03724422 - HO Prophylaxis Therapy for Distal Humerus Fractures N/A
Recruiting NCT03731130 - Prospective Observational Trial to Evaluate Quality of Life After Neoadjuvant Radiation or Chemoradiation Followed by Surgery in Patients With Rectal Cancer
Recruiting NCT04983095 - Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer Phase 3
Recruiting NCT05721053 - Improving Outcomes for Older Adults Undergoing Radiation Therapy
Active, not recruiting NCT04764227 - Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) Phase 2
Not yet recruiting NCT05821452 - Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma Phase 2
Recruiting NCT05335148 - Study to Evaluate the Safety of Colchicine Phase 1
Recruiting NCT04362306 - Radiation Oncology Patient Medical Physics Intervention Study N/A
Completed NCT01917890 - Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer N/A
Not yet recruiting NCT05648253 - Hyivy Device in Post-radiation Patients N/A
Completed NCT03235427 - The CAROLE (CArdiac Related Oncologic Late Effects) Study
Recruiting NCT03142425 - Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy
Recruiting NCT05406063 - Stereotactic Multiple Fraction Radiotherapy for Non-spine Bone Metastases N/A
Recruiting NCT03213925 - Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer Phase 2
Recruiting NCT03071289 - A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer Phase 3
Recruiting NCT06128863 - Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial Phase 2
Recruiting NCT05351294 - Assessment of Early Radiation Oncology Involvement Alongside Standard Oncologic Care in the Managemet Phase 3